ArticleJournal of diabetes science and technology2012
GlucoMen Day continuous glucose monitoring system: a screening for enzymatic and electrochemical interferents.
Article in Journal of diabetes science and technology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- The Impact of Interfering Substances on Continuous Glucose Monitors: Part 4: Continuous Glucose Monitoring Interferents: In Vivo Performance, Clinical Implications and Future Standardization.Journal of diabetes science and technology · 2026Review
- The Impact of Interfering Substances on Continuous Glucose Monitors Part 3: A Review of Non-Labeled Substances Influencing Continuous Glucose Monitor Readings.Journal of diabetes science and technology · 2026Review
- The Impact of Interfering Substances on Continuous Glucose Monitors: Part 2: Marketed Continuous Glucose Monitoring Designs, Labeled Interfering Substances, and Design Mitigations.Journal of diabetes science and technology · 2026Review
- Laboratory Protocol and Pilot Results for Dynamic Interference Testing of Continuous Glucose Monitoring Sensors.Journal of diabetes science and technology · 2024Article
- The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications.Frontiers in endocrinology · 2024Review
- Design of the micropump and mass-transfer compartment of a microfluidic system for regular nonenzymatic glucose measurement.Biotechnology reports (Amsterdam, Netherlands) · 2022Article
- Semi-Implantable Bioelectronics.Nano-micro letters · 2022Review
- Potentio-tunable FET sensor having a redox-polarizable single electrode for the implementation of a wearable, continuous multi-analyte monitoring device.Analytical and bioanalytical chemistry · 2022Article
- Microdialysis techniques and microdialysis-based patient-near diagnostics.Analytical and bioanalytical chemistry · 2022Review
- Use of Continuous Glucose Monitoring in the Assessment and Management of Patients With Diabetes and Chronic Kidney Disease.Frontiers in endocrinology · 2022Review
- Wireless and battery-free platforms for collection of biosignals.Biosensors & bioelectronics · 2021Review
- In Vitro Sugar Interference Testing With Amperometric Glucose Oxidase Sensors.Journal of diabetes science and technology · 2019Article
- Interference Assessment of Various Endogenous and Exogenous Substances on the Performance of the Eversense Long-Term Implantable Continuous Glucose Monitoring System.Diabetes technology & therapeutics · 2018Article
- Interstitium versus Blood Equilibrium in Glucose Concentration and its Impact on Subcutaneous Continuous Glucose Monitoring Systems.European endocrinology · 2014Article
- Pitfalls in hemoglobin A1c measurement: when results may be misleading.Journal of general internal medicine · 2014Review
- Minimizing the impact of time lag variability on accuracy evaluation of continuous glucose monitoring systems.Journal of diabetes science and technology · 2012Article
- Italian contributions to the development of continuous glucose monitoring sensors for diabetes management.Sensors (Basel, Switzerland) · 2012Review
- Interference testing: why following standards is not always the right thing to do.Journal of diabetes science and technology · 2012Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile most of the common drugs with the potential to interfere with continuous glucose monitoring (CGM) systems are accessible over the counter and can be assumed by CGM patients without medical supervision, many other chemicals are frequently used to treat critically ill patients. Continuous glucose monitoring reading accuracy may also be compromised in patients characterized by abnormally high concentrations of physiological interferents. In this article, 22 species selected from endogenous and exogenous chemicals were screened as possible interferents of GlucoMen®Day (GMD), the new microdialysis-based CGM system from A. Menarini Diagnostics.
methodInterference testing was performed according to the EP7-A2 guideline (Clinical and Laboratory Standards Institute 2005). Interference was evaluated at two levels of glucose, with each interferent additionally tested at two concentrations. Furthermore, two configurations of the GMD disposable sensor kit--one designed for subcutaneous application, the other for direct intravascular CGM--were challenged with interferent-spiked serum and blood samples, respectively.
resultsWith the exception of dopamine (however, at very high, nonphysiological concentrations), no interference was observed for all the tested substances. Interestingly, none of the common electrochemical interferents (including ascorbic acid, acetaminophen, and salicylic acid, which represent the major specificity issue for the competing CGM systems) significantly affected the system's output.
conclusionsThese results provide clear insights into the advantages offered by the use of a microdialysis-based CGM system that additionally relies on the detection of hydrogen peroxide at low operating potential. GlucoMen Day may become the CGM system of choice for those patients who require either regular administration of drugs or their glycemia to be tightly controlled in the intensive care unit or similar environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.